Literature DB >> 18176865

Autoantibody-mediated disorders of the central nervous system.

Sarosh Irani1, Bethan Lang.   

Abstract

Autoimmunity has been demonstrated in a diverse range of peripheral neurological disorders, such as myasthenia gravis and acquired neuromyotonia. Serum antibodies found in these conditions are directed against ion channels and receptors situated on the cell surface and have been shown to produce pathogenic effects. The symptoms of these peripheral disorders have been transferred to animals by passive or active immunisation and, in humans, treated successfully with immunomodulatory therapy. Recently, a number of central nervous system disorders (CNS), such as limbic encephalitis, certain forms of epilepsy, neuromyelitis optica and cerebellar ataxia, have been hypothesised to associate with specific serum autoantibodies. In this article we consider this rapidly expanding field of CNS disorders, discuss evidence for their proposed autoimmune aetiology and review whether the antibodies detected have been shown to be pathogenic or if they are secondary to preceding neuronal damage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18176865     DOI: 10.1080/08916930701619490

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  12 in total

1.  Autoimmune limbic encephalitis.

Authors:  T Wingfield; C McHugh; A Vas; A Richardson; E Wilkins; A Bonington; A Varma
Journal:  Clin Med (Lond)       Date:  2012-02       Impact factor: 2.659

Review 2.  The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.

Authors:  Alina Sesarman; Gestur Vidarsson; Cassian Sitaru
Journal:  Cell Mol Life Sci       Date:  2010-03-09       Impact factor: 9.261

3.  Glycine receptor antibodies in PERM: a new channelopathy.

Authors:  Pilar Martinez-Martinez; Peter C Molenaar; Mario Losen; Marc H de Baets
Journal:  Brain       Date:  2014-08       Impact factor: 13.501

4.  Association between schizophrenia and an autoimmune bullous skin disease-pemphigus: a population-based large-scale study.

Authors:  K Kridin; S Zelber-Sagi; D Comaneshter; A D Cohen
Journal:  Epidemiol Psychiatr Sci       Date:  2017-09-25       Impact factor: 6.892

5.  Paraneoplastic limbic encephalitis presenting as a neurological emergency: a case report.

Authors:  Zongqi Xia; Brijesh P Mehta; Allan H Ropper; Santosh Kesari
Journal:  J Med Case Rep       Date:  2010-03-24

6.  Severe central and peripheral paraneoplastic demyelination associated with tumours of the ovaries.

Authors:  Elzbieta Jurkiewicz; Katarzyna Kotulska; Katarzyna Nowak; Katarzyna Malczyk; Julita Borkowska; Małgorzata Bilska
Journal:  Childs Nerv Syst       Date:  2015-05-13       Impact factor: 1.475

7.  Association between C-reactive protein and risk of schizophrenia: An updated meta-analysis.

Authors:  Zhichao Wang; Ping Li; Dianyuan Chi; Tong Wu; Zubing Mei; Guangcheng Cui
Journal:  Oncotarget       Date:  2017-05-18

8.  Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients.

Authors:  Nick Willcox; Pilar Martinez-Martinez; Mario Losen; Alejandro M Gomez; Kathleen Vrolix; Jonas Hummel; Gisela Nogales-Gadea; Abhishek Saxena; Hans Duimel; Fons Verheyen; Peter C Molenaar; Wim A Buurman; Marc H De Baets
Journal:  J Immunol       Date:  2014-06-27       Impact factor: 5.422

9.  A significant causal association between C-reactive protein levels and schizophrenia.

Authors:  Masatoshi Inoshita; Shusuke Numata; Atsushi Tajima; Makoto Kinoshita; Hidehiro Umehara; Masahito Nakataki; Masashi Ikeda; Souichiro Maruyama; Hidenaga Yamamori; Tetsufumi Kanazawa; Shinji Shimodera; Ryota Hashimoto; Issei Imoto; Hiroshi Yoneda; Nakao Iwata; Tetsuro Ohmori
Journal:  Sci Rep       Date:  2016-05-19       Impact factor: 4.379

Review 10.  The epidemiologic evidence linking autoimmune diseases and psychosis.

Authors:  Michael E Benros; William W Eaton; Preben B Mortensen
Journal:  Biol Psychiatry       Date:  2013-10-03       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.